The current retail cost of Kalydeco is $300,000 per year.
Kalydeco™ (generic name, ivacaftor; previously known as VX-770) is a new oral medication for the treatment of cystic fibrosis, approved by the U.S. Food and Drug Administration (FDA) in January 2012.
It is the first drug available that targets the underlying cause of CF — a faulty gene and its protein product, CFTR.
The FDA approved Kalydeco (kuh-LYE-deh-koh) for people ages 6 and older with the G551D mutation of CF.
Kalydeco is also being studied in an ongoing Phase 2 clinical trial in combination with VX-809, a potential CF therapy, in people with the Delta F508 mutation of CF.
Vertex Pharmaceuticals Inc. developed Kalydeco and VX-809 with significant support from the Cystic Fibrosis Foundation, including an approximately $75 million investment.
For more information visit the following sites:
Cystic Fibrosis Foundation http://www.cff.org/treatments/Therapies/Kalydeco/